SHIFT Newsroom · GLOBAL

Trial record: incretin therapies in obesity-related HFpEF

Registry status checked on 3 October 2026: recruiting.

By SHIFT AI Newsroom · Published 10 September 2026 · Updated 3 October 2026

How we prepare and check newsroom articles · Report a correction

ClinicalTrials.gov lists NCT07554638, concerning incretin therapies in obesity-related HFpEF, as recruiting. The record was first posted on 2026-04-28 and last updated on 2026-08-24; SHIFT checked it on 3 October 2026.

This registration cannot support a blanket claim that all evidence about incretin therapies in HFpEF is unknown. Its own findings need to be distinguished from results of other trials.

No results tables were posted in this registry record when checked. That does not establish that no results have been published elsewhere. A registry entry is not a UK marketing authorisation or confirmation of NHS access.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

Keep the trial status, published results and UK treatment access separate. Do not change treatment on the basis of a registration.

Sources and evidence

ClinicalTrials.gov — Source date: 24 August 2026

← Back to SHIFT Newsroom